Discover Eos Bioinnovation's commitment to advancing sustainable biotechnology through innovative research and development. Explore our mission and services.
Mentions in press and media 5
| Date | Title | Description |
| 13.05.2026 | Autoimmunity BioSolutions Raises $1M in Seed Extension Funding | Autoimmunity BioSolutions (ABS), a Houston, TX-based biotechnology company developing a personalized, genetically-guided immuno-corrective therapy, raised $1M in Seed Extension funding. The round was led by Eos BioInnovation and a select gr... |
| 13.05.2026 | Autoimmunity BioSolutions Expands Seed Round To $3.1 Million To Advance Genetically Guided Autoimmune Therapy Platform | Autoimmunity BioSolutions announced the close of a $1 million seed extension financing round, bringing the company’s total seed funding to $3.1 million. The financing was anchored by Eos BioInnovation alongside participation from several fa... |
| 14.01.2026 | TECregen Secures CHF 10 Million, Appoints Chairman to Propel Immune Rejuvenation | Swiss biotech TECregen secured CHF 10 million in seed funding. This investment propels its pioneering thymus-rejuvenating biologics. The goal: restore robust immune function, counter age-related decline, and tackle serious diseases. Boehrin... |
| 09.01.2026 | CHF 10 million seed funding and new board chair for TECregen | Alongside the Boehringer Ingelheim Venture Fund (BIVF) TECregen’s funding round saw participation from LifeSpan Vision Ventures, Carma Fund, EOS BioInnovation, High-Tech Gründerfonds (HTGF), the JFG Life Sciences Foundation of the Univers... |
| 08.01.2026 | TECregen Raises CHF 10 Million Seed Round, Names Dr. Bo Rode Hansen Chairman | Basel, Switzerland-based TECregen has raised CHF 10 million (approximately €10.7 million / $12.6 million) in seed financing to advance a new class of thymus-rejuvenating biologics aimed at restoring immune function by rejuvenating thymic ep... |